Recent News

• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.06.2025 - Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
• 06.06.2025 - Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
• 06.06.2025 - Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
• 06.04.2025 - Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
• 06.04.2025 - Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
• 06.04.2025 - Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
• 05.27.2025 - Stifel 2025 Virtual Ophthalmology Forum
• 05.27.2025 - Stifel 2025 Virtual Ophthalmology Forum

Recent Filings

• 06.04.2025 - 8-K Current report
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 3 Initial statement of beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - 144 Report of proposed sale of securities